• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    88.84 -0.19 (-0.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Axsome Thera

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
    Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    2 Top Biotech Stocks to Buy in October
    Growth catalysts lie ahead for both of these players. 
    Via The Motley Fool
    Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Ratings for Axsome Therapeutics
    Via Benzinga
    2 Top Biotech Stocks Defying the Bear Market
    The best may be yet to come for these companies. 
    Via The Motley Fool
    2 No-Brainer Biotech Stocks to Buy Right Now
    You can get in early on these potential winners. 
    Via The Motley Fool
    Analyst Ratings for Axsome Therapeutics
    Via Benzinga
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
    A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
    Via Investor's Business Daily
    Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Expert Ratings for Axsome Therapeutics
    Via Benzinga
    Axsome Therapeutics to Present at Three Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    The Top Healthcare Stocks to Buy With $100
    Both stocks have outperformed the broader market in the last 12 months. 
    Via The Motley Fool
    These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
    Today's market loser could be tomorrow's market winner. 
    Via The Motley Fool
    Got $200? 3 Growth Stocks to Buy That Could Double Your Money
    There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
    Via The Motley Fool
    Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
    A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
    Via Investor's Business Daily
    3 Explosive Stocks to Buy Right Now
    These stocks are poised to pop in the not-too-distant future. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
    Via Benzinga
    DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
    Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
    Via Benzinga
    FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
    Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
    Via Benzinga
    Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
    AXSM earnings call for the period ending June 30, 2023. 
    Via The Motley Fool
    Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    3 Fantastic Growth Stocks to Buy in August
    These stocks could be poised to soar. 
    Via The Motley Fool
    Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
    There's lots of upside potential for these drugmakers. 
    Via The Motley Fool
    The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
    These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
    Via InvestorPlace
    Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday
    Keybanc boosted the price target for Camping World Holdings, Inc. (NYSE: CWH) from $28 to $36. Keybanc analyst Noah Zatzkin maintained an Overweight rating. Camping World shares rose 1.4% to $32.04 in... 
    Via Benzinga
    Got $500? 3 Growth Stocks to Buy That Could Double Your Money
    There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good. 
    Via The Motley Fool
    Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
    Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time 
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.